Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Lipton

Showing results (121-130 of 148) with videos related to

Pageof 15
Sort By:
Critical Reviews in Oncology/Hematology|March 18, 2011
Consensus on the utility of bone markers in the malignant bone disease settingRobert Coleman, Luis Costa, Fred Saad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2003
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancerBruce E Hillner, James N Ingle, Rowan T Chlebowski, et al.
Journal of Bone Oncology|February 25, 2016
Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trialsRobert E Coleman, Allan Lipton, Luis Costa, et al.
International Journal of Cancer|June 21, 2018
High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohortsAllan Lipton, Kim Leitzel, Suhail M Ali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind studyAlison T Stopeck, Allan Lipton, Jean-Jacques Body, et al.
Lung Cancer (Amsterdam, Netherlands)|June 18, 2011
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancerRadj Gervais, John D Hainsworth, Normand Blais, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2010
Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patientsJeff Sperinde, Xueguang Jin, Jayee Banerjee, et al.
Cancer Treatment Reviews|May 19, 2010
Metastasis and bone loss: advancing treatment and preventionRobert E Coleman, Allan Lipton, G David Roodman, et al.
Cancer|January 28, 2003
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastasesJean-Jacques Body, Philip Greipp, Robert E Coleman, et al.
Cancer Research|October 19, 2011
Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypesNgoc-Han Ha, Vasudha S Nair, Divijendra Natha Sirigiri Reddy, et al.
Pageof 15

Showing results (121-130 of 148) with videos related to

Sort By:
Pageof 15
Critical Reviews in Oncology/Hematology|March 18, 2011
Consensus on the utility of bone markers in the malignant bone disease settingRobert Coleman, Luis Costa, Fred Saad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2003
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancerBruce E Hillner, James N Ingle, Rowan T Chlebowski, et al.
Journal of Bone Oncology|February 25, 2016
Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trialsRobert E Coleman, Allan Lipton, Luis Costa, et al.
International Journal of Cancer|June 21, 2018
High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohortsAllan Lipton, Kim Leitzel, Suhail M Ali, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind studyAlison T Stopeck, Allan Lipton, Jean-Jacques Body, et al.
Lung Cancer (Amsterdam, Netherlands)|June 18, 2011
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancerRadj Gervais, John D Hainsworth, Normand Blais, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2010
Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patientsJeff Sperinde, Xueguang Jin, Jayee Banerjee, et al.
Cancer Treatment Reviews|May 19, 2010
Metastasis and bone loss: advancing treatment and preventionRobert E Coleman, Allan Lipton, G David Roodman, et al.
Cancer|January 28, 2003
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastasesJean-Jacques Body, Philip Greipp, Robert E Coleman, et al.
Cancer Research|October 19, 2011
Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypesNgoc-Han Ha, Vasudha S Nair, Divijendra Natha Sirigiri Reddy, et al.
Pageof 15